RCT of Russian IDU Peer Network HIV Prevention Intervention - 1
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to conduct a randomized controlled trial to assess the efficacy of a peer-educator intervention focused on injection drug users and their drug and sexual networks. We expect that participants who receive the intervention will demonstrate a reduction in the rate of HIV infection and HIV risk behaviors and members of their risk network will also demonstrate reductions in risk behaviors compared to those in the control group.
| Condition | Intervention | Phase |
|---|---|---|
|
HIV Infections |
Behavioral: Peer mentor intervention |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Investigator) Primary Purpose: Prevention |
| Official Title: | Randomized Controlled Trial of Russian IDU Peer Network HIV Prevention Intervention |
- Incident number of HIV Infections in social networks [ Time Frame: 1 year ] [ Designated as safety issue: No ]
- Self reported risk behaviors: entry into drug treatment, cessation of drug use [ Time Frame: 1 year ] [ Designated as safety issue: No ]
- Self reported risk behaviors: number of sex partners, freq of condom use [ Time Frame: 3 months ] [ Designated as safety issue: No ]
| Enrollment: | 400 |
| Study Start Date: | October 2003 |
| Study Completion Date: | June 2009 |
| Primary Completion Date: | June 2009 (Final data collection date for primary outcome measure) |
-
Behavioral: Peer mentor intervention
Intravenous drug use (IDU) is driving the HIV epidemic in Russia; over 90% of all HIV-1 infections have occurred within communities of IDUs. In St. Petersburg (population 5 million), the prevalence of HIV infection in IDUs (estimated population 100,000) leapt from 4% in 1999 to 12% in 2000. At present there are an estimated 5-7 million IDUs, a four-fold increase since the end of the Soviet Union. In St. Petersburg, there has been a three-fold increase in regular IDUs and a nine-fold increase in teenage IDUs during the past five years.
The intervention to be tested in this study draws upon theoretical and empirical evidence suggesting that peer educator programs can have significant effects on the risk-related behaviors of both the educators and the peers whom they educate. Providing peer educator training to IDUs may efficiently cultivate sustainable protective behavioral norms related to injection and sexual risk among the IDU educators' social networks. Prior studies have demonstrated that peer educator programs can realize such normative changes, and it is hypothesized in this study that these normative changes will be reflected in significant reductions in the rates of HIV transmission among the peer educators and the members of their social networks.
Comparison condition: Informed by the Centers for Disease Control model of best practice" standard of care of HIV testing and counseling, participants in the comparison condition will receive risk reduction education and motivational counseling to reduce their risk behaviors.
Eligibility| Ages Eligible for Study: | 16 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Of legal age to independently provide written informed consent for research
- Report having injected drugs at least 12 times in the last three months
- HIV seronegative (ELISA confirmed)
- Willing and able to recruit at least three HIV risk network members who are eligible for study participation
Exclusion Criteria:
- Prior or concurrent enrollment in the last 6 months in another HIV behavioral or biomedical prevention study
- Psychological disturbance or cognitive impairment that appears to limit the ability to understand study procedures, as determined by clinic staff
- Any other condition that, in the opinion of the investigator, would make participation in the study unsafe, or otherwise interfere with the study objectives
Contacts and LocationsPlease refer to this study by its ClinicalTrials.gov identifier: NCT00218673
| Russian Federation | |
| Biomedical Center | |
| St. Petersburg, Russian Federation, 197110 | |
| Principal Investigator: | Carl Latkin, Ph.D. | Johns Hopkins University |
More Information
No publications provided by Johns Hopkins Bloomberg School of Public Health
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Carl Latkin, JHU |
| ClinicalTrials.gov Identifier: | NCT00218673 History of Changes |
| Other Study ID Numbers: | DESPR DA016142, 5R01DA016142-05, 5R01DA016142-04, 5R01DA016142-03, 5R01DA016142-02, 1R01DA016142-01, R01-16142-1, NIDA-16142-1 |
| Study First Received: | September 16, 2005 |
| Last Updated: | May 19, 2011 |
| Health Authority: | United States: Federal Government |
ClinicalTrials.gov processed this record on February 27, 2015